tru-015
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00479622)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD20BINDING AGENT
B-lymphocyte antigen CD20 binding agent
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297845 ↗
Also known as
- tru-015
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00634933 | Phase 2 | Mar 1, 2008 | Pfizer, Trubion Pharmaceuticals |
| NCT00521638 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2007 | Emergent BioSolutions, Pfizer, Wyeth |
| NCT00479622 | Phase 1 | Aug 1, 2007 | Emergent BioSolutions, Pfizer, Wyeth |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 2 | 2007 |
| Emergent BioSolutions | For profit | 2 | 0 | 2 | 2007 |
| Wyeth | For profit | 2 | 0 | 2 | 2007 |
| Trubion Pharmaceuticals | For profit | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1